Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed133%
unknown133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCT06372210
terminatedphase_3

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCT03892889
unknownphase_4

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449

Clinical Trials (3)

Showing 3 of 3 trials
NCT06372210Not Applicable

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Completed
NCT03892889Phase 3

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Terminated
NCT03881449Phase 4

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3